** Shares of Royalty Pharma gain 5.73% to $27.70 premarket
** Co says it will pay about $1.1 billion to acquire RP Management, which manages the healthcare firm's operations, to simplify its corporate structure
** RPRX buys royalties of future drugs from academic labs and biotechs
** The acquisition will generate cash savings of greater than $100 million in 2026 and greater than $175 million in 2030 and drive cumulative savings of greater than $1.6 billion over 10 years, RPRX says
** Co adds its board has also approved a new $3 billion share repurchase program
** Co intends to repurchase $2 billion of shares in 2025, subject to market conditions
** RPRX stock fell ~9% in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.